Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis

Bloom, S, Kiilerich, S, Lassen, M R, Forbes, A ORCID: https://orcid.org/0000-0001-7416-9843, Leiper, K, Langholz, E, Irvine, E J, O'Morain, C, Lowson, D and Orm, S (2004) Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics, 19 (8). pp. 871-878. ISSN 0269-2813

Full text not available from this repository. (Request a copy)

Abstract

Heparin has anti-inflammatory and immunomodulatory activity which may be of therapeutic benefit in the treatment of ulcerative colitis.

Item Type:	Article
Uncontrolled Keywords:	adolescent,adult,aged,aged, 80 and over,colitis, ulcerative,double-blind method,female,fibrinolytic agents,heparin, low-molecular-weight,humans,male,middle aged,patient compliance,prospective studies,treatment outcome
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Gastroenterology and Gut Biology Faculty of Medicine and Health Sciences > Research Groups > Nutrition and Preventive Medicine
Depositing User:	Pure Connector
Date Deposited:	06 Aug 2014 10:38
Last Modified:	20 Oct 2022 23:59
URI:	https://ueaeprints.uea.ac.uk/id/eprint/49619
DOI:	10.1111/j.1365-2036.2004.01926.x

Actions (login required)

View Item